Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single‐Dose, Matched Case‐Control Study

This phase I open‐label trial (NCT03627754) assessed glasdegib pharmacokinetics and safety in otherwise healthy participants with moderate (Child‐Pugh B) or severe (Child‐Pugh C) hepatic impairment. Participants with hepatic impairment and age/weight‐matched controls with normal hepatic function rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Masters, Joanna C., LaBadie, Robert R., Salageanu, Joanne, Li, Jerry, Shaik, Naveed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359308/
https://www.ncbi.nlm.nih.gov/pubmed/33356019
http://dx.doi.org/10.1002/cpdd.897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359308/
https://www.ncbi.nlm.nih.gov/pubmed/33356019
http://dx.doi.org/10.1002/cpdd.897

Ejemplares similares